Imunon Stock (NASDAQ:IMNN)

Forecast Ownership Financials Chart Transcripts

Previous Close

$1.89

52W Range

$1.70 - $8.19

50D Avg

$2.10

200D Avg

$3.28

Market Cap

$4.61M

Avg Vol (3M)

$51.66K

Beta

1.95

Div Yield

IMNN Company Profile

Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Mar 01, 1999

Website

IMNN Performance

IMNN Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-14.65B	$-19.13M	$-21.03M
Net Income	$-14.49M	$-18.62M	$-19.51M
EBITDA	$-14.65M	$-17.90M	$-19.88M
Basic EPS	$-6.83	$-21.10	$-28.14
Diluted EPS	$-6.83	$-21.10	$-28.14

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q1 26May 12, 26 | 11:00 AM

Q4 25Mar 31, 26 | 11:00 AM

Q3 25Nov 13, 25 | 11:00 AM

Peer Comparison

Ticker	Company
MRKR	Marker Therapeutics, Inc.
DWTX	Dogwood Therapeutics, Inc.
BOLT	Bolt Biotherapeutics, Inc.
EVGN	Evogene Ltd.
COCP	Cocrystal Pharma, Inc.
CING	Cingulate Inc.
CLRB	Cellectar Biosciences, Inc.
TRAW	Traws Pharma, Inc.